LTRNLantern Pharma Inc.Signing up patients
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Adenocarcinoma of Lung · Carcinoma, Non-Small-Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 90 (planned)
- Started
- Mar 1, 2023
- Main results expected
- Dec 2026
- Fully finished
- Jun 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS)
Measured over: Through study completion, an average of 2 years
Overall survival (OS)
Measured over: Through study completion, an average of 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05456256 · record last updated 2026-05-04 · checked 2026-11-09 15:47 UTC